Subject: VPH Newsletter: May 2021

2nd International School on In Silico Trials 
6 -10 September 2021 online, every afternoon from 15 to 19 CEST

In the past few years, it became possible, in some cases, to provide evidence of safety and efficacy for new medical products using modelling and simulation, what is now referred to as In Silico Trials.

This could be a game-changer, but it is also a disruptive innovation that may require some changes in the business model of many companies.

The 2nd International School on In Silico Trials will offer a systematic, non-specialist review on the strengths and the weakness of in silico trials technologies. The participants will be guided in the development of a better and deeper understanding of the threats and opportunities that this unprecedented technology presents, with the goal to enable more informed decision-making on the adoption of these innovations.

The school this year is organized by methods. After an introduction of the Director Prof. Marco Viceconti, a world-class expert will present a specific modelling method, illustrate it around a specific exemplar use case, and provide a critical review of the pros and cons of such method. We will lecture on molecular dynamics, systems biology, machine learning, computational fluid dynamics, finite element modelling, and agent-based modelling. We will also lecture on the use of high-performance computing, and the challenges posed by multiphysics and multiscale models. We will close with a systematic SWOT analysis of the adoption of In Silico Trials in the average biomedical company, and a review of the current regulatory landscape.

- Avicenna Alliance provides feedback on the EU roadmap on the evaluation and revision of the general pharmaceutical legislation
The Avicenna Alliance has submitted its feedback to the inception impact assessment on the EU general pharmaceuticals legislation. Through this feedback, Avicenna Members provided the European Commission with guidance on how to meet unmet medical needs, maintain a system of incentives, promote evidence generation tools for marketing authorisation of innovative medicines, and support and accelerate product development as well as authorisation.
- The European Commission publishes long-awaited draft regulation package on AI
At the end of April the European Commission published its long-awaited regulation package on AI, including new rules and actions to position Europe as a hub for trustworthy AI application. 
- EU Health Policy Platform Calls for Proposals: 2021 Thematic Networks
The EC is inviting public health stakeholders to submit initiatives for anew cycle of Thematic Networks under the EU Health Policy Platform. The purpose is to produce a Joint Statement within a year, summarising the common position of a group of stakeholder organisations in different public health areas.
Early Stage Researcher opportunity in Sheffield
International Master 2 Cardiac EP: Electromechanical Heart Diseases
This training will be an integral part of the environment at Liryc - University of Bordeaux from October 2021. Applications until June 11.
In the literature
- 2021 VPH Barcellona Summer School
The 5th VPH Summer School will focus on Tackling Complexity in Health & Medicine.
- VPHi Keynote webinar: How to write a scientific paper 
- VPHi keynote webinar: Imaging of joint tissues. Webinar recordings and slides 
- European Research and Innovation Days
- CMBBE 2021 Symposium 
- EUROPIN summer school of drug design 
- EMA workshop on artificial intelligence in medicines regulation
- VPH 2022 Conference
"The Virtual Physiological Human will revolutionise the way health knowledge is produced stored and managed as well as the way in which healthcare is currently delivered."
 European Commission
LikeTwitterPinterestGooglePlus LinkedInForward
Celestijnenlaan 300C, 3001, Heverlee, Belgium
You may unsubscribe or change your contact details at any time.